Skip to main content
Premium Trial:

Request an Annual Quote

Annalisa Jenkins

PlaqueTec has appointed Annalisa Jenkins its CEO. She will lead the company's launch in 2018 of its biomarker-based PlaqueTec Liquid Biopsy System, which is being developed to improve risk assessment and enable earlier intervention in the management of coronary artery disease. The system collects biomarkers directly associated with plaques whtin coronary arteries in order to assess residual inflammatory risk. Jenkins formerly was the CEO of Dimension Therapeutics. Prior to that, she was Executive Vice President, Head of Global R&D for Merck Serono.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.